• 1
    Aschan J. Allogeneic haematopoietic stem cell transplantation: current status and future outlook. Br Med Bull. 2006; 77-78: 23-36.
  • 2
    Ringden O, LeBlanc K. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS. 2005; 113: 813-830.
  • 3
    Tierney DK, Facione N, Padilla G, et al. Response shift: a theoretical exploration of quality of life following hematopoietic cell transplantation. Cancer Nurs. 2007; 30: 125-138.
  • 4
    Syrjala KL, Langer SL, Abrams JR, et al. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol. 2005; 23: 6596-6606.
  • 5
    Andrykowski MA, Bishop MM, Hahn EA, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem cell transplantation. J Clin Oncol. 2005; 23: 599-608.
  • 6
    Harder H, Van Gool AR, Cornelissen JJ, et al. Assessment of pre-treatment cognitive performance in adult bone marrow haemopoeitic stem cell transplantation patients: a comparative study. Eur J Cancer. 2005; 41: 1007-1016.
  • 7
    Booth-Jones M, Jacobsen PB, Ransom S, et al. Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant. 2005; 36: 695-702.
  • 8
    Jacobs SR, Small BJ, Booth-Jones M, et al. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer. 2007; 110: 1560-1567.
  • 9
    Syrjala KL, Dikmen S, Langer SL, et al. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood. 2004; 104: 3386-3392.
  • 10
    Schulz-Kindermann F, Mehnert A, Scherwath A, et al. Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007; 39: 789-799.
  • 11
    Beglinger LJ, Duff K, Van Der Heiden S, et al. Neuropsychological and psychiatric functioning pre- and posthematopoietic stem cell transplantation in adult cancer patients: a preliminary study. J Int Neuropsychol Soc. 2007; 13: 172-177.
  • 12
    Harder H, Duivenvoorden HJ, Van Gool AR, et al. Neurocognitive functions and quality of life in haematological patients receiving haematopoietic stem cell grafts: a 1-year follow-up pilot study. J Clin Exp Neuropsychol. 2006; 28: 283-293.
  • 13
    Sostak P, Padovan CS, Yousry TA, et al. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology. 2003; 60: 842-848.
  • 14
    Ahles TA, Tope DM, Furstenberg C, et al. Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol. 1996; 14: 1457-1462.
  • 15
    Meyers CA, Weitzner M, Byrne K, et al. Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol. 1994; 12: 820-826.
  • 16
    Parth P, Dunlap WP, Kennedy RS, et al. Motor and cognitive testing of bone marrow transplant patients after chemoradiotherapy. Percept Motor Skills. 1989; 68: 1227-1241.
  • 17
    Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006; 12: 138-151.
  • 18
    Hurria A, Somlo G, Ahles T. Renaming “chemobrain.” Cancer Invest. 2007; 25: 373-377.
  • 19
    Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006; 81: 973-988.
  • 20
    Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006; 81: 104-130.
  • 21
    Nakao K, Treas J. Computing 1989 Prestige Scores. GSS Methodological Report No. 70. Chicago, Ill: NORC; 1990.
  • 22
    Mason CF, Lemmon D, Wayne KS, et al. Shipley Institute of Living Scale: formulas for abstraction quotients from a normative sample of 580. Sex and socioeconomic status considered as additional moderating variables. Psychol Assess. 1991; 3: 412-417.
  • 23
    McHorney CA, Ware JE, Raczek AE. The MOS 36-item, short-form health survey (SF-36): psychometric and clinical uses of validity in measuring physical and mental constructs. Med Care. 1993; 331: 247-263.
  • 24
    Cella DR, Jacobsen PB, Orav EJ, et al. A brief POMS measure of distress for cancer patients. J Chron Dis. 1987; 40: 939-942.
  • 25
    First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for Axis I DSM-IV Disorders. Patient ed (SCID-I/P), version 2.0. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1994.
  • 26
    Harder H, Corenlissen JJ, van Gool AR, et al. Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer. 2002; 95: 183-192.
  • 27
    Andrykowski M, Schmitt FA, Gregg ME, et al. Neuropsychologic impairment in adult bone marrow transplant candidates. Cancer. 1992; 70: 2288-2297.
  • 28
    Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. New York, NY: Oxford University Press; 2006.
  • 29
    Strub RL, Black FW. The Mental Status Examination in Neurology. Philadelphia, Pa: F.A. Davis Company; 1980.
  • 30
    Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974; 24: 1019-1025.
  • 31
    Psychological Assessment Resources, Inc. Grooved Pegboard. Lutz, Fla: Psychological Assessment Resources, Inc.; 2000.
  • 32
    Lezak, MD, Howieson, DB, Loring, DW. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.
  • 33
    Mitrushina M, Boone KB, Razani J, et al. Handbook of Normative Data for Neuropsychological Assessment. 2nd ed. New York, NY: Oxford University Press; 2005.
  • 34
    Larrabee GJ, Trahan DE, Levin HS. Normative data for a 6-trial administration of the verbal selective reminding test. Clin Neuropsychol. 2000; 14: 110-118.
  • 35
    Ruff RM, Parker SB. Gender- and age-specific changes in motor speed and eye-hand coordination in adults: normative values for the finger tapping and grooved pegboard test. Percept Mot Skills. 1993; 62: 407-416.
  • 36
    Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004; 19: 203-214.
  • 37
    Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for 2 measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 1999; 14: 167-177.
  • 38
    Ware JE, Kosinski M. SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1. 2nd ed. Lincoln, RI: Quality Metric Incorporated; 2001.
  • 39
    Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft versus host disease after marrow transplantation from unrelated donors. Blood. 2000; 96: 2062-2068.
  • 40
    Cull A, Hay C, Love SB, et al. What do patients mean when they complain of concentration and memory problems? Br J Cancer. 1996; 74: 1674-1679.
  • 41
    Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer. 2008; 112: 2577-2592.
  • 42
    Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol. 2006; 24: 5101-5104.